On 10 May, the German Forschungszentrum Jülich center, one of the largest interdisciplinary research centres in Europe, announced the successful completion of the Phase I trial investigating the drug candidate PRI-002 for the treatment of Alzheimer’s disease (AD). The Phase I trial was a randomised, double-blind and placebo-controlled single ascending-dose study evaluating the safety and tolerability of PRI-002 in healthy volunteers. PRI-002 is a peptide developed to directly destroy the toxic oligomers without the involvement of the immune system. Findings showed that PRI-002 was well tolerated in healthy participants after administering the experimental drug daily for four weeks. These results allow a further development of the drug candidate. Researchers are now planning to show the drug’s efficacy in Phase II trial.
